Court Says Pfizer's Biosimilar of J&J's Remicade Doesn't Infringe Patent
August 17 2016 - 6:00PM
Dow Jones News
Pfizer Inc.'s lower-priced version of Johnson & Johnson's
blockbuster autoimmune disease drug Remicade doesn't infringe a
patent, a federal court ruled on Wednesday, potentially clearing
the way for the drug's sale in October.
J&J said it would appeal the decision and affirmed its sales
projections.
Remicade, first approved for sale in the U.S. in 1998, is
J&J's largest product by sales, accounting for $6.56 billion in
sales last year, including $4.5 billion in the U.S. The drug's two
lead indications are inflammatory bowel disease, including Crohn's
disease and ulcerative colitis, and rheumatoid arthritis and
associated indications.
The so-called biosimilar to infliximab was developed by South
Korea's Celltrion Inc. and is already available in Europe and
Canada.
Pfizer acquired rights to sell the so-called biosimilar drug in
some markets, including the U.S. and Canada, as part of its Hospira
acquisition last year.
U.S. health regulators approved the drug in June, and Pfizer
indicated it planned to start selling it in early October,
following the required 180-day marketing notice.
Write to Maria Armental at maria.armental@wsj.com
(END) Dow Jones Newswires
August 17, 2016 18:45 ET (22:45 GMT)
Copyright (c) 2016 Dow Jones & Company, Inc.
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Apr 2024 to May 2024
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From May 2023 to May 2024